Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

510
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
510
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

639
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
639
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

262
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
262
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

568
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
568
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

128
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
128
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

437
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
437

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Step Toward Diversity and Inclusion in Cardiovascular Research Trials.

Journal of the American College of Cardiology·2026
Same author

Intravascular Imaging-Guided Percutaneous Coronary Intervention: Transforming Precision and Outcomes in Contemporary Practice.

Journal of clinical medicine·2025
Same author

HRS/ACC Scientific Statement: Guiding Principles on the Performance of Intracardiac Ablation Procedures in Ambulatory Surgical Centers.

Journal of the American College of Cardiology·2025
Same author

HRS/ACC scientific statement: Guiding principles on the performance of intracardiac ablation procedures in ambulatory surgical centers.

Heart rhythm·2025
Same author

Economic Barriers to Interventional Cardiology Care for Adults and Children With Congenital Heart Disease and Potential Policy Solutions: A SCAI Policy Statement.

Journal of the Society for Cardiovascular Angiography & Interventions·2025
Same author

Cardiovascular disease risk assessment from circulating lipid particles-A new challenge for physicians.

The American journal of medicine·2025

Related Experiment Video

Updated: Aug 24, 2025

Cooling or Warming the Esophagus to Reduce Esophageal Injury During Left Atrial Ablation in the Treatment of Atrial Fibrillation
06:25

Cooling or Warming the Esophagus to Reduce Esophageal Injury During Left Atrial Ablation in the Treatment of Atrial Fibrillation

Published on: March 15, 2020

9.7K

Clopidogrel-induced Pill Oesophagitis.

James C Blankenship1, Matthew J Shellenberger2

  • 1Department of Cardiology, Geisinger Medical Center, Danville, PA, USA.

Heart International
|October 24, 2022
PubMed
Summary

Patients taking clopidogrel (an antiplatelet agent) during percutaneous coronary intervention (PCI) can develop pill esophagitis, causing chest pain. Prompt conservative treatment effectively resolved symptoms and esophageal inflammation.

Keywords:
Oesophagitisclopidogrelcoronary stenting

More Related Videos

Use of the Scissor-Type Knife During the Peroral Endoscopy Myotomy Procedure for the Treatment of Achalasia
06:42

Use of the Scissor-Type Knife During the Peroral Endoscopy Myotomy Procedure for the Treatment of Achalasia

Published on: March 3, 2023

3.2K
Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

2.9K

Related Experiment Videos

Last Updated: Aug 24, 2025

Cooling or Warming the Esophagus to Reduce Esophageal Injury During Left Atrial Ablation in the Treatment of Atrial Fibrillation
06:25

Cooling or Warming the Esophagus to Reduce Esophageal Injury During Left Atrial Ablation in the Treatment of Atrial Fibrillation

Published on: March 15, 2020

9.7K
Use of the Scissor-Type Knife During the Peroral Endoscopy Myotomy Procedure for the Treatment of Achalasia
06:42

Use of the Scissor-Type Knife During the Peroral Endoscopy Myotomy Procedure for the Treatment of Achalasia

Published on: March 3, 2023

3.2K
Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

2.9K

Area of Science:

  • Cardiology
  • Gastroenterology
  • Pharmacology

Background:

  • Antiplatelet agents are standard for preventing coronary stent thrombosis post-procedure.
  • Pill ingestion in a supine position can lead to esophageal discomfort or complications.

Purpose of the Study:

  • To report a rare case of clopidogrel-induced pill esophagitis following percutaneous coronary intervention (PCI).
  • To highlight the clinical presentation and successful conservative management of this complication.

Main Methods:

  • A case report detailing a patient undergoing PCI who ingested clopidogrel.
  • Clinical observation of symptoms, diagnostic endoscopy, and treatment response.

Main Results:

  • The patient developed chest pain and diagnosed pill esophagitis after PCI and clopidogrel ingestion.
  • Conservative management led to symptom resolution and endoscopic evidence of healing.

Conclusions:

  • Pill esophagitis is a potential, albeit rare, complication of ingesting medications like clopidogrel during or after PCI.
  • Conservative treatment is effective for managing clopidogrel-induced pill esophagitis.